Chemylix - Strategy

At Chemylix, we believe that the decline in the pharmaceutical R&D productivity is rooted in the much deeper dynamic of chemistry convergence.

The striking persistence of the industry-wide trend indeed suggests that the failure point lies upstream of the development process, at the origin of the drug discovery enterprise:
the chemistry itself.

It demands that the novelty & relevance of the chemical spaces being routinely explored be appraised with renewed ingenuity: indeed, chemists across the industry spectrum tend to focus, access & prospect the same molecular reservoirs in very much the same way because of the shared similarity of targets, tools, knowledge & training.

These chemical sources have been overexploited and, not surprisingly, they are now drying up.

Chemylix invented the Molecular Foundry™ synthetic engine to purposely transcend the traditional frontiers of pharmaceutical chemistry & gain access to genuinely pristine molecular fields.